SCHEMBL5788917

SCHEMBL5788917

CC(C)(C)OC(=O)N(CCO)CCC(=O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA14 Q9ULX7 2/20 0.49
SSTR4 P31391 1/20 0.42
ALDH1A1 P00352 1/20 0.36
ALDH2 P05091 1/20 0.36
HDAC6 Q9UBN7 2/20 0.36
HDAC1 Q13547 2/20 0.36
HDAC2 Q92769 2/20 0.36
TDP1 Q9NUW8 1/20 0.35
NAALAD2 Q9Y3Q0 1/20 0.34
HDAC3 O15379 1/20 0.33
NCOR2 Q9Y618 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA7 P43166 1/20 0.33
CAMK2A Q9UQM7 1/20 0.31
TSHR P16473 1/20 0.31
DGAT1 O75907 1/20 0.31
MEN1 O00255 1/20 0.30
GAA P10253 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2499626 0.93 CA14 (0.50) CA14SSTR4ALDH1A1ALDH2HDAC6
SCHEMBL2580993 0.91 CA14 (0.49) CA14SSTR4ALDH1A1ALDH2HDAC6
SCHEMBL503444 0.89 CA14 (0.53) CA14SSTR4ALDH1A1ALDH2HDAC6
SCHEMBL12901425 0.87 CA14 (0.58) CA14ALDH1A1ALDH2HDAC6HDAC1
SCHEMBL28584989 0.87 CA14 (0.51) CA14SSTR4HDAC6HDAC1HDAC2
SCHEMBL745378 0.87 CA14 (0.51) CA14SSTR4HDAC6HDAC1HDAC2
SCHEMBL16120760 0.86 CA14 (0.45) CA14SSTR4HDAC6HDAC1HDAC2
SCHEMBL17987028 0.86 CA14 (0.45) CA14ALDH1A1ALDH2HDAC6HDAC1
SCHEMBL20089215 0.86 CA14 (0.45) CA14SSTR4ALDH1A1ALDH2HDAC6
SCHEMBL5916355 0.84 CA14 (0.43) CA14SSTR4HDAC6HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2968591-A1 CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF Novartis AG (CH) 2016-01-20 EP disclosed
WO-2014151030-A1 CELL PROLIFERATION INHIBITORS AND CONJUGATES THEREOF NOVARTIS AG (CH) 2014-09-25 WO disclosed
EP-1385524-A4 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO KG (DE) 2006-02-01 EP disclosed
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 US disclosed
CN-1520298-A Pyrazolopyrimidines as therapeutic agents �����ʩ���عɷݹ�˾ 2004-08-11 CN disclosed
EP-1212327-B8 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO KG (DE) 2004-02-25 EP disclosed
EP-1385524-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS Abbott GmbH & Co. KG (DE) 2004-02-04 EP disclosed
US-6660744-B1 Kinase inhibitors ABBOTT GMBH & CO. KG (DE) 2003-12-09 US disclosed
EP-1212327-B1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AG (DE) 2003-08-20 EP disclosed
CN-1390219-A Pyrazolopyrimidines as therapeutic agents ABBOTT AG (DE) 2003-01-08 CN disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 US disclosed
WO-2002080926-A1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS ABBOTT GMBH & CO. KG (DE) 2002-10-17 WO disclosed
EP-1212327-A2 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AKTIENGESELLSCHAFT (DE) 2002-06-12 EP disclosed
WO-2001019829-A2 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AKTIENGESELLSCHAFT (DE) 2001-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 CA14 4647/4885SSTR4 1396/4885ALDH1A1 99/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.